EGFR抑制剂耐药机制的研究进展及治疗策略

EGFR是调节细胞内环境稳态的一种酪氨酸激酶,其与配体结合后可影响细胞增殖、凋亡、迁移、存活、血管生成和肿瘤发生等一系列复杂过程,EGFR抑制剂已逐渐应用于临床肿瘤治疗。但随着时间的推移,EGFR抑制剂靶向治疗出现了耐药现象。本文将对EGFR抑制剂的研究现状及耐药机制做一简短的概述,冀希为优化、整合EGFR靶向治疗提供参考。

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis. Following ligand binding, EGFR influences cell proliferation, apoptosis, migration, survival, angiogenesis, tumorigenesis and complex processes. EGFR inhibitors has gradually applied to clinical oncology. But with the passage of time, the EGFR inhibitors targeted therapy appeared resistance phenomenon. In this review, we provide a brief overview regarding the present research situation and mechanisms of resistance to EGFR inhibitors. Hope for providing the reference to optimize and integrate EGFR targeted therapy.